Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON34342
NL-OMON34342
Recruiting
Not Applicable

Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer) - Donor leukapheresis for T-cell receptor gene therapy

ederlands Kanker Instituut0 sites2 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsmelanomaSkin cancer10040900

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
melanoma
Sponsor
ederlands Kanker Instituut
Enrollment
2
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
ederlands Kanker Instituut

Eligibility Criteria

Inclusion Criteria

  • •Patient with a stage IV melanoma
  • •Minimum age 18
  • •ECOG performance status max. 1
  • •HLA\-A@\-positive patients
  • •negative for hepatitis A, B, C and HIV
  • •Thrombocytes at least 100\*109/L
  • •Erythrocytes at least ... \*109/L
  • •Hemoglobin at least 5 mmol/L
  • •Leukocytes at least ... \*109/L
  • •ALAT/ASAT less than three times the upper limit of normal

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementpersistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2012-003691-40-NLeiden University Medical Center
Completed
Phase 2
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementlymfomenleukemialymphoma10024324
NL-OMON37016eids Universitair Medisch Centrum4
Recruiting
Not Applicable
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.head and neck squamous cell carcinomamaligne melanomaskin canceruveal melanoma100300541002765610040900
NL-OMON52657Erasmus MC, Universitair Medisch Centrum Rotterdam20
Not yet recruiting
Phase 1/2
MAGE-C2 TCR T cell therapy
2024-516922-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20
Not yet recruiting
Not Applicable
Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility studyLiver CancerPrimary Liver Cell Carcinoma100196541000381610019815
NL-OMON47991Erasmus MC, Universitair Medisch Centrum Rotterdam35